Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Overview | Financials
Company Name | Ultragenyx Pharmaceutical Inc. |
Symbol | RARE |
Currency | USD |
Price | 40.98 |
Market Cap | 3,784,269,414 |
Dividend Yield | 0% |
52-week-range | 37.02 - 60.37 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
Website | https://www.ultragenyx.com |
An error occurred while fetching data.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD